Eli Lilly and Co. (NYSE: LLY) reported revenue growth of 44.7% and earnings per share growth of 95.58% for the fiscal year ending 31 December 2025, based on a comparative financial analysis published on 11 June 2026. LLY reported EPS of $23.00 for fiscal 2025 and posted a gross profit margin of 83%, a net profit margin of 32%, and a return on equity of 77.78%.

LLY shares closed at $1,132.89 as of the most recent available trading data, within a 52-week range of $619.40 to $1,166.29. LLY carries a price-to-earnings ratio of 40.2 and a price-to-sales ratio of 14.82. EV/EBITDA stands at 43.26x. Market capitalisation is $1,071 billion, with approximately 945 million shares outstanding and institutional ownership at 72% of shares. LLY is a constituent of the S&P 500 index. A one-year investment of $1,000 in LLY would have returned approximately $1,490, reflecting total shareholder return of approximately 49%.

LLY's five-year compound annual growth rate for total revenue stands at 21.58%, compared to Roche Holding AG's (OTC: RHHBY) five-year revenue CAGR of 0.98%. Over the same period, LLY achieved a five-year EPS CAGR of 27.52% versus RHHBY's 8.56%, and a five-year net profit CAGR of 27.22% versus RHHBY's negative 2.06%.

LLY's return on assets for fiscal 2025 is 18.35%, compared to RHHBY's 13.7%. Its return on capital employed is 33.31%, compared to RHHBY's 23.35%. LLY's current ratio of 1.58 exceeds RHHBY's 1.38, reflecting stronger short-term liquidity.

LLY ranks first among 11 pharmaceutical companies on the NYSE by market capitalisation. The stock offers an annual dividend per share of $6.00, equivalent to a trailing yield of 0.57%. EPS growth from Q4 2025 to Q1 2026 was 11.9%.